Oxcarbazepine in the treatment of borderline personality disorder: A pilot study

Journal of Clinical Psychiatry

Volumn 66, Issue 9, 2005, Pages 1111-1115

  Bellino, Silvio ^a   Paradiso, Erika ^a   Bogetto, Filippo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

OXCARBAZEPINE;

ADULT; ARTICLE; BORDERLINE STATE; CLINICAL ARTICLE; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPONATREMIA; MALE; NAUSEA; PILOT STUDY; PRIORITY JOURNAL; RATING SCALE; SEDATION; SIDE EFFECT;

EID: 26644475186     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n0904     Document Type: Article

References (57)

1. American Psychiatric Association. Practice Guidelines for the Treatment of Patients With Borderline Personality Disorder. Am J Psychiatry 2001;158(suppl 10):1-52
2. Zanarini MC, Frankenburg FR, Gunderson JG. Pharmacotherapy of borderline outpatients. Compr Psychiatry 1988;29:372-378
3. Gardner DL, Cowdry RW. Pharmacotherapy of borderline personality disorder: a review. Psychopharmacol Bull 1989;25:515-523
4. Goldberg SC. Prediction of change in borderline personality disorder. Psychopharmacol Bull 1989;25:550-555
5. Links PS, Steiner M, Boiago I, et al. Lithium therapy for borderline patients: preliminary findings. J Clin Psychopharmacol 1990;4:173-181
6. Stein DJ. Drug treatment of the personality disorders. Br J Psychiatry 1992;161:167-184
7. Wilcox JA. Divalproex sodium in the treatment of aggressive behaviour. Ann Clin Psychiatry 1994;6:17-20
8. Stein DJ, Simeon D, Frenkel M, et al. An open trial of valproate in borderline personality disorder. J Clin Psychiatry 1995;56:506-510
9. Wilcox JA. Divalproex sodium as a treatment for borderline personality disorder. Ann Clin Psychiatry 1995;7:33-37
10. Kavoussi RJ, Coccaro EF. Divalproex sodium for impulsive aggressive behaviour in patients with personality disorder. J Clin Psychiatry 1998; 59:676-680
11. Davis LL, Ryan W, Adinoff B, et al. Comprehensive review of the psychiatric uses of valproate. J Clin Psychopharmacol 2000;20:1S-17S
12. Hollander E, Allen A, Lopez RP, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001;62:199-203
13. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 2002;63:442-446
14. Zanarini MC, Frankenburg FR, Hennen J, et al. Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years. J Clin Psychiatry 2004;65:28-36
15. Gardner DL, Cowdry RW. Positive effects of carbamazepine on behavioural dyscontrol in borderline personality disorder. Am J Psychiatry 1986;143:519-522
16. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 1988;45:111-119
17. Denicoff KD, Meglathery SB, Post RM, et al. Efficacy of carbamazepine compared with other agents: a clinical practice survey. J Clin Psychiatry 1994;55:70-77
18. Hori A. Pharmacotherapy for personality disorders. Psychiatry Clin Neurosci 1998;52:13-19
19. Pinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord 1998;51:333-343
20. Green B. Lamotrigine in mood disorders. Curr Med Res Opin 2003; 19:272-277
21. Preston GA, Marchant BK, Reimherr FW, et al. Borderline personality disorder in patients with bipolar disorder and response to lamotrigine. J Affect Disord 2004;79:297-303
22. Ghaemi SN, Ko JY. Oxcarbazepine treatment of bipolar disorder: a review of the literature. Primary Psychiatry 2002;9:55-59
23. Emrich H. Studies with oxcarbazepine (Trileptal) in acute mania. Int Clin Psychopharmacol 1990;5(suppl 1):83-88
24. Hellewell JS. Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability. J Affect Disord 2002;72 (suppl 1):S23-S34
25. Hummel B, Walden J, Stampfer R, et al. Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design. Bipolar Disord 2002;4:412-417
26. Dietrich DE, Kropp S, Emrich HM. Oxcarbazepine in the treatment of affective and schizoaffective disorders [in German]. Fortschr Neurol Psychiatr 2003:71:255-264
27. Evins AE. Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. J Clin Psychiatry 2003;64(suppl 8):9-14
28. Ghaemi SN, Berv DA, Klugman J, et al. Oxcarbazepine treatment of bipolar disorder. J Clin Psychiatry 2003;64:943-945
29. Perugi G, Toni C, Frare F, et al. An open case study in Italy of oxcarbazepine, an effective mood stabilizer, in patients with drug resistant/ intolerant bipolar I disorders [poster]. Presented at the 16th Congress of European College of Neuropsychopharmacology; Sept 20-24, 2003; Prague, Czech Republic
30. Raja M, Azzoni A. Oxcarbazepine vs valproate in mood and schizoaffective disorders. Int J Neuropsychopharmacol 2003;6:409-414
31. Benedetti A, Lattanzi L, Pini S, et al. Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode. J Affect Disord 2004;79:273-277
32. Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 2004;6:57-75
33. Stahl SM. Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels [BRAINSTORMS]. J Clin Psychiatry 2004;65:738-739
34. Yatham LN. Newer anticonvulsants in the treatment of bipolar disorder. J Clin Psychiatry 2004;65(suppl 10):28-35
35. American Psychiatric Association. Practice Guidelines for the Treatment of Patients With Bipolar Disorder [revision]. Am J Psychiatry 2002;159(suppl4):1-50
36. Suppes T, Dennehy EB, Swann AC, et al. Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder 2000. J Clin Psychiatry 2002;63:288-299
37. Gentry JR. Hill C, Malcolm R. New anticonvulsants: a review of applications for the management of substance abuse disorders. Ann Clin Psychiatry 2002;14:233-245
38. Leweke FM, Gerth CW, Koethe D, et al. Oxcarbazepine as an adjunct for schizophrenia [letter]. Am J Psychiatry 2004;161:1130-1131
39. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000
40. First MB, Gibbon M, Spitzer RL, et al. Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II). Washington, DC: American Psychiatric Press; 1997
41. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
42. Ventura J, Green M, Shaner A, et al. Training and quality assurance with the Brief Psychiatry Rating Scale: "the drift busters." Int J Psychiatr Res 1993;3:221
43. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
44. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959:32:50-55
45. Goldman HH, Skodol AE, Lave TR. Revising Axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry 1992; 149:1148-1156
46. Arntz A, van den Hoorn M, Cornells J, et al. Reliability and validity of the borderline personality disorder severity index. J Personal Disord 2003:17:45-59
47. Schmidt D, Arroyo S, Baulac M, et al. Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view. Acta Neurol Scand 2001;104:167-170
48. Pinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord 1998;51:333-343
49. Siever LJ, Davis KL. A psychobiological perspective on the personality disorders. Am J Psychiatry 1991;148:1647-1658
50. Silverman JM, Pinkham L, Horvath TB, et al. Affective and impulsive personality disorder traits in the relatives of patients with borderline personality disorder. Am J Psychiatry 1991;148:1378-1385
51. Deltito J, Martin L, Riefkohl J, et al. Do patients with borderline personality disorder belong to the bipolar spectrum? J Affect Disord 2001;67:221-228
52. Perugi G, Akiskal HS. The soft bipolar spectrum redefined: focus on the cyclothymic, anxious-sensitive, impulse-dyscontrol, and binge-eating connection in bipolar II and related conditions. Psychiatr Clin North Am 2002;25:713-737
53. Akiskal HS, Antouche EG, Allilaire JF. Bipolar II with and without cyclothymic temperament: "dark" and "sunny" expressions of soft bipolarity. J Affect Disord 2003;73:49-57
54. Perugi G, Toni C, Traverso MC, et al. The role of cyclothymia in atypical depression: toward a data-based reconceptualization of the borderline-bipolar II connection. J Affect Disord 2003;73:87-98
55. Clarkin JF, Hull JW, Hurt SW. Factor structure of borderline personality disorder criteria. J Personal Disorder 1993;7:137-143
56. Sanislow CA, Grilo CM, McGlashan TH. Factor analysis of the DSM-III-R border personal criteria in psychotic inpatients. Am J Psychiatry 2000;157:1629-1633
57. Sanislow CA, Grilo CM, Morey CL, et al. Confirmatory factor analysis of DSM-IV criteria for borderline personality disorder: findings from the Collaborative Longitudinal Personality Disorders Study. Am J Psychiatry 2002;159:284-290